Three Betadine(r) products, known and used in many homes, hospitals, and
dental clinics across South Africa, have proven effective against the novel
coronavirus (SARS-CoV-2) that causes COVID-19.
The products tested include Betadine(r) Mouthwash and Gargle, Betadine(r)
Surgical Scrub, and Betadine(r) Antiseptic Solution. Laboratory testing
conducted at the Duke-NUS Medical School in Singapore showed strong in-vitro
virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds1,
and in the Tropical Infectious Diseases Research and Education Center
(TIDREC) study at the University of Malaysia9, direct evidence was presented
of the virucidal activity of Betadine(r) Mouthwash & Gargle and against
SARS-CoV-2 in just 15 seconds.
Mundipharma, the distributor of Betadine(r) products, announced these
results after the TIDREC research9 was accepted by the British Dental
Journal (BDJ) and published as a Letter on 26 June 2020, and the Duke-NUS
research was published in the respected Infectious Disease and Therapy
Journal on 08 July 20201.
Betadine(r) products contain povidone-iodine (PVP-I), which has been widely
used throughout the world as an antiseptic since the middle of last century.
Shannon te Roller, General Manager of Mundipharma South Africa, says,
“Betadine(r) products with PVP-I have been well accepted in South Africa
for home use and by the medical community for decades, with benefits that
include no reported antimicrobial resistance, fast-acting, a long-lasting
effect, and extremely low allergenicity on skin 3.”
The TIDREC research concludes that the broad-spectrum antimicrobial and
rapid virucidal activity of PVP-I products against SARS-CoV-2 suggests its
importance in infection control. It goes on to note that, as an additional
protective barrier to PPE, these products may reduce disease transmission.
PVP-I is easily administered and has been used in both hospital and
community settings for more than 55 years* and can thus be readily
integrated into existing infection control protocols. PVP-I based products
can be used as part of infection control measures during the COVID-19
pandemic and can augment health and hygiene measures to reduce the spread of
Up-to-the-minute scientific research7,8,9 backs up the use and efficacy of
Betadine(r) against the novel coronavirus, and across the world in a variety
of medical disciplines including orthopaedic surgery10, dentistry and dental
surgery, and ENT surgery 11, 12 13. The use of PVP-I has been recommended in
protocols in response to the COVID-19 pandemic. In SA, the South African
Dental Association (SADA), recommends its use during patient treatment and
pre-operatively, stating that, to this end, the most important method for
reducing the viable bacterial and viral load is through pre-procedural
rinsing with PVP-I (0.23% to 1%) or 1% hydrogen peroxide rinse2.
Betadine(r) Mouthwash and Gargle is recommended for use for infections of
mouth and throat at full strength, or as a mouthwash, diluted one part with
two parts of water; Betadine(r) Surgical Scrub is used for disinfecting
hands in the medical and dental profession; and Betadine(r) Antiseptic
Ointment is used to effectively stop bacteria, fungi, and viruses from
infecting injuries caused by minor daily accidents.
Past studies have also shown that PVP-I has the broadest antimicrobial
activity of available antiseptics and has been used to combat the spread of
infection against a wide range of viruses, including highly pathogenic and
low pathogenic influenza viruses (H1N1, H3N2, H1N2, H5N3, H7N7, and HpN2),
and SARS and MERS coronaviruses. In all instances, rapid virucidal activity
has been demonstrated with both Betadine(r) Mouthwash and Gargle and
Betadine(r) Surgical Scrub3,4,5,6.